Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

VolitionRx Limited (VNRX)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
3.3600-0.1200 (-3.45%)
At close: 4:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.4800
Open3.4400
Bid3.3400 x 4000
Ask3.7400 x 2200
Day's Range3.3500 - 3.4400
52 Week Range2.8500 - 6.6700
Volume82,707
Avg. Volume96,533
Market Cap177.719M
Beta (5Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-0.4320
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • GlobeNewswire

    Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to LifeSciencesInvestorForum.com to view presentationsNEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the September 16th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live executive presentations and interactive discussions focused on publicly traded companies in the life sciences

  • GlobeNewswire

    Life Sciences Virtual Investor Conference: Company Executives Present Live September 16th

    Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.comNEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. Individual investors, institutional

  • Zacks Small Cap Research

    VNRX: Revenues from Nu.Q Vet Cancer Screening Test steady from beta test; Silver One expected to generate revenues in late 2021.

    By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT VolitionRx (NYSE:VNRX) is engaged in multiple epigenetic projects based on company’s proprietary Nu.QTM platform that has developed numerous blood-based clinical assays . The beta launch of Nu.Q Vet Cancer Screening Test is currently generating revenue, and management is in active discussions with a ranger of smaller and

Advertisement
Advertisement